Morocco - Press Releases

Fourth quarter Adjusted EBITDA1of $428million and full year Adjusted EBITDA of $1,690 million

Milestone Commemorated with Savings for Prep and Exam Purchases

PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.

-Ascend Advanced Therapies nombra a John Chiminski como presidente y a Karen Flynn como directora independiente

NEW YORK, March 5, 2025 /PRNewswire/ --Lucid Diagnostics Inc.(Nasdaq: LUCD)("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced registered direct offering of 13,939,331 shares of common stock at a purchase price of $1.10 per share.

Tampa General Hospital Cancer Institute hosted a day of keynotes, presentations and discussions at TGH Brooksville to address the challenges facing cancer patients in rural communities.

CHICAGO, March 5, 2025 /PRNewswire/ -- TheRobert Spadoni Scholarship for Entrepreneurs is now accepting applications from undergraduate students nationwide who demonstrate exceptional entrepreneurial potential. Established by healthcare executive Robert Spadoni, this $1,000 scholarship supports students committed to creating positive change through entrepreneurial ventures.

DURHAM, N.C., March 5, 2025 /PRNewswire/ --Pluto Health, a Duke-University spin-out, is now a qualified Medicaid provider in TN. The company integrates care delivery with its proprietary platform that leverages AI and data science to deliver convenient care options and health services for patients. This milestone strengthens Pluto Health's commitment to delivering comprehensive, accessible, and high-quality care to patients across the state, particularly those in underserved communities.

WASHINGTON, March 5, 2025 /PRNewswire/ --Paralyzed Veterans of AmericaChief Executive Officer Carl Blake releases statement following the leak of an internal memorevealing the Department of Veterans Affairs' plan to reduce its overall staffing of the department to FY 2019 levels - a decrease of more than 80,000 positions from the current staffing level.

With global cancer incidence rising and a strong clinical pipeline exploring combination therapies, the XPOVIO addressable market is expanding. Despite competition from CAR-T and novel therapies, XPOVIO's oral administration and unique mechanism offer differentiation.

The increasing occurrence of chronic and infectious diseases is the main driver of the rising demand for interferon. Furthermore, advancements in interferon production and ongoing research and development of innovative interferon therapies are key factors fueling the expansion of the interferon market from 2025 to 2032.

SAN FRANCISCO, March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The rising prevalence of chronic illnesses such as diabetes, cardiovascular diseases, and cancer is greatly boosting the demand for biosensors, as these conditions necessitate frequent monitoring for proper management. Likewise, the increasing need for point-of-care testing (POCT) is propelling market growth, as biosensors offer fast and convenient diagnostic solutions beyond conventional healthcare facilities.

MINNEAPOLIS, March 5, 2025 /PRNewswire/ -- People who take over-the-counter pain relievers after a concussion may recover faster than those who do not take pain relievers, according to a preliminary study released March 5, 2025, that will be presented at the American Academy of Neurology's 77th Annual Meeting taking place April 5-9, 2025, in San Diego and online.

-Drugs found to be safe and effective overall despite some risk of eye damage

No Shareholder Action Required at this Time

SUZHOU, China, March 5, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Phase Ib clinical trial application in Australia for CS5001, its ROR1-targeting antibody-drug conjugate (ADC), in combination with first-line standard-of-care (SoC) for DLBCL. CS5001 is also being evaluated as both a monotherapy and in combination with a PD-L1 inhibitor for advanced solid tumors in an ongoing global multi-center clinical trial.

HONG KONG, March 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab, the world's first PD-1/CTLA-4 bispecific antibody independently developed by the company, as an adjuvant treatment for hepatocellular carcinoma (HCC) with high recurrence risk following curative resection or ablation.

- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions -

SCOTTSDALE, Ariz., March 5, 2025 /PRNewswire/ -- Axon (Nasdaq: AXON) ("Axon") announced today that it has priced $1,000.0 million aggregate principal amount of its Senior Notes due 2030 (the "2030 Notes") at an issue price of 100% and $750.0 million aggregate principal amount of its Senior Notes due 2033 at an issue price of 100% (the "2033 Notes" and, together with the 2030 Notes, the "Notes") in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). The total offering size was increased from the previously announced total offering size of $1,500.0 million aggregate principal amount of Notes. Axon intends to use the net proceeds of this offering for general corporate purposes, which may include, among other things, potentially repurchasing or redeeming Axon's 0.50% Convertible Senior Notes due 2027 (the "Existing Convertible Notes"), and providing capital to support Axon's growth and to acquire or invest in product lines, products, services or technologies. The sale of the Notes is expected to close on March 11, 2025, subject to customary closing conditions.

CHATTANOOGA, Tenn., March 5, 2025 /PRNewswire/ -- Miller Industries, Inc. (NYSE: MLR) ("Miller Industries" or the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2024.

CLEVELAND, March 5, 2025 /PRNewswire/ --

PEMBROKE, Bermuda, March 5, 2025 /PRNewswire/ -- Gold Reserve Ltd. (TSX.V: GRZ) (OTCQX: GDRZF) announced today that its wholly owned subsidiary, GR Mining (Barbados) Inc. (GR Mining), filed a request for arbitration against the Bolivarian Republic of Venezuela ("Venezuela") under the Additional Facility Rules of the International Centre for the Settlement of Investment Disputes of the World Bank in Washington, D.C.

HOUSTON, March 5, 2025 /PRNewswire/ --The Sterling Group ("Sterling"), a middle market private equity firm, announced today that it has completed the sale ofFrontline Road Safety ("Frontline" or the "Company") to Bain Capital. Frontline is the largest provider of pavement marking and ancillary services in the U.S. Financial terms of the private transaction were not disclosed.

Debuting on Saturday,Arden at Bedfordoffers exceptional new homes with open layouts